Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 288 • 2014 ACR/ARHP Annual Meeting
Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis
Esi M. Morgan DeWitt¹, Bin Huang^2,3, Kimberly Barnett⁴, Adam Carle⁵, Constance Mara⁶ and Karon Cook⁷, ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ³Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, ⁴Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Patient reported outcome measures (PROs) are used increasingly in clinical care. A framework to interpret scores according to degree of clinical severity would enhance…
Abstract Number: 279 • 2014 ACR/ARHP Annual Meeting
Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care
Alysha Taxter¹, Keshia Maughn², Edward M. Behrens³ and Pamela F. Weiss⁴, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose National registry cross-sectional data show significant differences in patient-reported outcomes (PROs) across juvenile idiopathic arthritis (JIA) subtypes. This study aimed to assess predictors of…
Abstract Number: 2904 • 2014 ACR/ARHP Annual Meeting
Clinical and Radiological Features of Down’s Arthropathy
Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland
Background/Purpose The ‘Arthropathy of Down syndrome’ was first described in 1984. Three decades on we still have limited literature on the clinical & radiological features…
Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…
Abstract Number: 2292 • 2014 ACR/ARHP Annual Meeting
Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort
Ginger L. Janow¹, Laura Schanberg², Soko Setoguchi³, Elizabeth D. Mellins⁴, Rayfel Schneider⁵, Yukiko Kimura^1,6 and The CARRA Registry Investigators⁷, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁷Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: Systemic JIA (sJIA) is a rare disease whose treatment has changed in the past 10 yrs. The Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
Abstract Number: 290 • 2014 ACR/ARHP Annual Meeting
Patterns of Active Joint Involvement in JIA
Simon W.M. Eng¹, Mira Van Veenendaal², Alan M. Rosenberg³, Kiem Oen⁴, Quaid Morris¹ and Rae S.M. Yeung², ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Pediatrics RR149 Rehab Ctr, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: JIA encompasses a set of heterogeneous diseases with chronic joint inflammation. Although the ILAR criteria consider joint counts, they do not reflect specific joint…
Abstract Number: 2294 • 2014 ACR/ARHP Annual Meeting
The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom
Timothy Beukelman¹, Roberto Carrasco², Yukiko Kimura³, Laura Schanberg⁴, Wendy Thomson⁵, Kimme L. Hyrich⁶, For the CARRA Registry Investigators⁷ and For the CAPS Investigators Group⁸, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁴Duke University, Durham, NC, ⁵Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷CARRA, Durham, NC, ⁸CAPS, Manchester, United Kingdom
Background/Purpose: Systemic JIA (sJIA) treatment has changed dramatically with the introduction of biologic agents, although treatment approaches may differ between countries. We characterized and compared…
Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Gerd Horneff¹, Carol A. Wallace², Pierre Quartier³, Daniel J. Kingsbury⁴, Kirsten Minden⁵, Mareike Bereswill⁶, Vishvas Garg⁷, Hartmut Kupper⁶ and Jasmina Kalabic⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴Randall Children's Hospital at Legacy Emanuel, Portland, OR, ⁵Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…
Abstract Number: 2208 • 2013 ACR/ARHP Annual Meeting
Psychological Condition Of JIA Patients Treated With Biologic Agents. – A Nation-Wide Survey In Japan
Yuki Osako¹, Yukiko Nonaka², Harumi Akaike², Tomohiro Kubota³, Tsuyoshi Yamatou², Tomokazu Nagakura⁴, Junko Yasumura⁵, Hiroyuki Imanaka² and Syuji Takei⁶, ¹School of Health Sciences, Faculty of Medicine,Department of Maternal & Child Nursing and Midwifery, Kagoshima University, Kagoshima city, Japan, ²Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ³Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴Department of Pediatrics, House of Meguminoseibo, Usuki, Japan, ⁵Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
Background/Purpose: Biologic agents, newly developed medications targeting for inflammatory cytokines such as TNF-alpha or IL-6, have been drastically improving the disease course of JIA who…
Abstract Number: 2168 • 2013 ACR/ARHP Annual Meeting
Temporomandibular Joint Involvement and Quality Of Life In Juvenile Idiopathic Arthritis
Paula Frid^1,2, Ellen Nordal^3,4, Francesca Bovis⁵, Denise Marafon⁵, Donato De Angelis⁵, Sheila Oliveira⁵, Fabrizia Corona⁵, Gabrieli Simonini⁵, Joyce Davidson⁵, Helen Foster⁵, Rik Joos⁵, Ivan Foeldvari⁵, Michel Steenks⁵, Pekka Lahdenne⁵, Pavla Dolezalova⁵, Elena Palmisani⁵, Alberto Martini⁵, Angela Pistorio⁵ and Nicolino Ruperto⁵, ¹Department of Otorhinolaryngology, Division of Oral and Maxillofacial Surgery, University Hospital North Norway, Tromso, Norway, ²Public Dental Service Competence Centre of Northen Norway, Tromso, Norway, ³Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, ⁴Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁵Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy
Background/Purpose: Temporomandibular joint (TMJ) arthritis in childhood is seen in a substantial percentage of children with Juvenile idiopathic arthritis (JIA) and may lead to reduced mouth…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Tamas Constantin¹, Ivan Foeldvari², Jelena Vojinovic³, Gerd Horneff⁴, Ruben Burgos-Vargas⁵, Irina Nikishina⁶, Jonathan Akikusa⁷, Tadej Avcin⁸, Jeffrey Chaitow⁵, Elena Koskova⁹, Bernard Lauwerys¹⁰, Jack Bukowski¹¹, Chuanbo Zang¹², Joseph Wajdula¹², Deborah Woodworth¹², Bonnie Vlahos¹³, Alberto Martini¹⁴ and Nicolino Ruperto⁵, ¹Semmelweis University, Budapest, Hungary, ²Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ³Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, ⁴Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵PRINTO, Genoa, Italy, ⁶Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁷Rheumatology, Royal Childrens Hospital, Parkville, Australia, ⁸The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹⁰Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc., Collegeville, PA, ¹³Department of Specialty Care, Pfizer Inc., Collegeville, PA, ¹⁴Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].